BACKGROUND: An increased incidence of breast carcinoma has been reported among relatives of individuals who are affected with the rare recessive disorder, ataxia-telangiectasia (A-T), and who are heterozygous for mutations in the ataxia-telangiectasia mutated (ATM) gene. However, most studies of breast carcinoma cases from the general population have failed to find a higher incidence of ATM mutations in cases when compared with controls. METHODS: Genomic DNA samples from 258 individuals were screened for mutations of all types in each of the 62 coding exons of the ATM gene; 142 of these were from breast carcinoma cases with a first-degree family history or early age at diagnosis, 35 were from cases selected for the presence of either known disease-related mutations (n = 25) or missense alterations of unknown consequences (n = 10) in BRCA1 or BRCA2, and 81 were from matched controls. RESULTS: A total of 12 individuals with ATM mutations were identified, 11 among 142 breast carcinoma cases (7.7%; 95% CI, 3.9-13.4%) and 1 among 81 controls (1.2%; 95% CI, 0.0-6.7%) (P = 0.06). All mutations detected were of the missense type; none were predicted to truncate the ATM protein. Among cases, mutations were found exclusively in patients with a family history of breast carcinoma (12.1%; 95% CI, 6.2-20.6%) (P = 0.02). Similar frequencies of ATM mutations were found in 35 additional cases selected for the presence of BRCA1 or BRCA2 mutations when compared with cases overall. CONCLUSIONS: ATM mutations, specifically missense mutations, are more common in breast carcinoma cases selected for first-degree family history and early age at diagnosis. Copyright 2001 American Cancer Society.
BACKGROUND: An increased incidence of breast carcinoma has been reported among relatives of individuals who are affected with the rare recessive disorder, ataxia-telangiectasia (A-T), and who are heterozygous for mutations in the ataxia-telangiectasia mutated (ATM) gene. However, most studies of breast carcinoma cases from the general population have failed to find a higher incidence of ATM mutations in cases when compared with controls. METHODS: Genomic DNA samples from 258 individuals were screened for mutations of all types in each of the 62 coding exons of the ATM gene; 142 of these were from breast carcinoma cases with a first-degree family history or early age at diagnosis, 35 were from cases selected for the presence of either known disease-related mutations (n = 25) or missense alterations of unknown consequences (n = 10) in BRCA1 or BRCA2, and 81 were from matched controls. RESULTS: A total of 12 individuals with ATM mutations were identified, 11 among 142 breast carcinoma cases (7.7%; 95% CI, 3.9-13.4%) and 1 among 81 controls (1.2%; 95% CI, 0.0-6.7%) (P = 0.06). All mutations detected were of the missense type; none were predicted to truncate the ATM protein. Among cases, mutations were found exclusively in patients with a family history of breast carcinoma (12.1%; 95% CI, 6.2-20.6%) (P = 0.02). Similar frequencies of ATM mutations were found in 35 additional cases selected for the presence of BRCA1 or BRCA2 mutations when compared with cases overall. CONCLUSIONS:ATM mutations, specifically missense mutations, are more common in breast carcinoma cases selected for first-degree family history and early age at diagnosis. Copyright 2001 American Cancer Society.
Authors: Eiji Kubota; Christopher T Williamson; Ruiqiong Ye; Anifat Elegbede; Lars Peterson; Susan P Lees-Miller; D Gwyn Bebb Journal: Cell Cycle Date: 2014-05-19 Impact factor: 4.534
Authors: Denise L Stredrick; Montserrat Garcia-Closas; Marbin A Pineda; Parveen Bhatti; Bruce H Alexander; Michele M Doody; Jolanta Lissowska; Beata Peplonska; Louise A Brinton; Stephen J Chanock; Jeffery P Struewing; Alice J Sigurdson Journal: Hum Mutat Date: 2006-06 Impact factor: 4.878
Authors: Sean V Tavtigian; Peter J Oefner; Davit Babikyan; Anne Hartmann; Sue Healey; Florence Le Calvez-Kelm; Fabienne Lesueur; Graham B Byrnes; Shu-Chun Chuang; Nathalie Forey; Corinna Feuchtinger; Lydie Gioia; Janet Hall; Mia Hashibe; Barbara Herte; Sandrine McKay-Chopin; Alun Thomas; Maxime P Vallée; Catherine Voegele; Penelope M Webb; David C Whiteman; Suleeporn Sangrajrang; John L Hopper; Melissa C Southey; Irene L Andrulis; Esther M John; Georgia Chenevix-Trench Journal: Am J Hum Genet Date: 2009-09-24 Impact factor: 11.025
Authors: Patrick Concannon; Robert W Haile; Anne-Lise Børresen-Dale; Barry S Rosenstein; Richard A Gatti; Sharon N Teraoka; T Anh Diep; Laila Jansen; David P Atencio; Bryan Langholz; Marinela Capanu; Xiaolin Liang; Colin B Begg; Duncan C Thomas; Leslie Bernstein; Jørgen H Olsen; Kathleen E Malone; Charles F Lynch; Hoda Anton-Culver; Jonine L Bernstein Journal: Cancer Res Date: 2008-08-15 Impact factor: 12.701
Authors: Tú Nguyen-Dumont; Florence Le Calvez-Kelm; Nathalie Forey; Sandrine McKay-Chopin; Sonia Garritano; Lydie Gioia-Patricola; Deepika De Silva; Ron Weigel; Suleeporn Sangrajrang; Fabienne Lesueur; Sean V Tavtigian Journal: Hum Mutat Date: 2009-06 Impact factor: 4.878
Authors: Larysa Poluben; Maneka Puligandla; Donna Neuberg; Christine R Bryke; Yahsuan Hsu; Oleksandr Shumeiko; Xin Yuan; Olga Voznesensky; German Pihan; Miriam Adam; Ernest Fraenkel; Roni Rasnic; Michal Linial; Sergiy Klymenko; Steven P Balk; Paula G Fraenkel Journal: Am J Hematol Date: 2018-10-31 Impact factor: 10.047